Clinical Trial Results

Showing: All studies [change]
Condition: Cancer Location: Iowa 25 trials found
New Search
Filter
Trial Phase
Study Type
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
PHASE2INTERVENTIONAL Chicago, Illinois +4 more
RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
PHASE3INTERVENTIONAL Kingman, Arizona +4 more
RECRUITING
Autoimmune Intervention Mastery Course Study
NAINTERVENTIONAL Iowa City, Iowa
RECRUITING
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NAINTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
PHASE2, PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
PHASE2, PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
PHASE1INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
GEMINI-NSCLC: NSCLC Biomarker Study
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
PHASE2INTERVENTIONAL Iowa City, Iowa +1 more
RECRUITING
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
PHASE1INTERVENTIONAL Chicago, Illinois +4 more
RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
PHASE1, PHASE2INTERVENTIONAL Duarte, California +4 more
RECRUITING
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
PHASE1INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
PHASE2INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
PHASE2, PHASE3INTERVENTIONAL Kingman, Arizona +4 more
RECRUITING
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
PHASE2INTERVENTIONAL Iowa City, Iowa +2 more
RECRUITING
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Newark, Delaware +4 more
RECRUITING
Beat Childhood Cancer Specimen Banking and Data Registry
N/AOBSERVATIONAL Little Rock, Arkansas +4 more
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
PHASE1, PHASE2INTERVENTIONAL Jacksonville, Florida +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type